We are analyzing https://link.springer.com/article/10.1007/s00262-005-0118-2.

Title:
Tumor progression despite massive influx of activated CD8+ T cells in a patient with malignant melanoma ascites | Cancer Immunology, Immunotherapy
Description:
Although melanoma tumors usually express antigens that can be recognized by T cells, immune-mediated tumor rejection is rare. In many cases this is despite the presence of high frequencies of circulating tumor antigen-specific T cells, suggesting that tumor resistance downstream from T cell priming represents a critical barrier. Analyzing T cells directly from the melanoma tumor microenvironment, as well as the nature of the microenvironment itself, is central for understanding the key downstream mechanisms of tumor escape. In the current report we have studied tumor-associated lymphocytes from a patient with metastatic melanoma and large volume malignant ascites. The ascites fluid showed abundant tumor cells that expressed common melanoma antigens and retained expression of class I MHC and antigen processing machinery. The ascites fluid contained the chemokines CCL10, CCL15, and CCL18 which was associated with a large influx of activated T cells, including CD8+ T cells recognizing HLA-A2 tetramer complexes with peptides from Melan-A and NA17-A. However, several functional defects of these tumor antigen-specific T cells were seen, including poor production of IFN-γ in response to peptide-pulsed APC or autologous tumor cells, and lack of expression of perforin. Although these defects were T cell intrinsic, we also observed abundant CD4+CD25+FoxP3+ T cells, as well as transcripts for FoxP3, IL-10, PD-L1/B7-H1, and indoleamine-2,3-dioxygenase (IDO). Our observations suggest that, despite recruitment of large numbers of activated CD8+ T cells into the tumor microenvironment, T cell hyporesponsiveness and additional negative regulatory mechanisms can limit the effector phase of the anti-tumor immune response.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Telecommunications

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

cells, article, pubmed, google, scholar, cas, tumor, cancer, melanoma, immunol, cell, gajewski, immunotherapy, microenvironment, regulatory, med, usa, chicago, privacy, cookies, content, research, immunology, ascites, peterson, thomas, nature, expression, immune, access, human, publish, search, activated, harlin, tumors, antigenspecific, lymphocytes, class, antigen, functional, effector, cytotoxic, peripheral, blood, tcell, responses, patients, res, data,

Topics {✒️}

t-cell-based active immunotherapy month download article/chapter observed abundant cd4+cd25+foxp3+ antigen-specific t-cell responses tcr/mhc-tumor peptide interactions peptide-specific primary cytotoxic cytotoxic t-cell induction pd-l1/b7h-1 inhibits anti-tumor immune response melanoma-invaded lymph nodes immune-mediated tumor rejection pd-l1/b7-h1 late-stage ovarian cancer circulating tumor antigen-specific human tumour immunology human tumor-specific cd8 article cancer immunology malignant melanoma ascites t-cell responses full article pdf rosenberg sa ascites fluid contained host immune system peptide-pulsed apc privacy choices/manage cookies cancer microenvironment cd8-positive human peripheral blood local functional tolerance cell-mediated rejection tumor resistance downstream pd-l1 blockade tumor cell evasion tumor antigen-specific autologous tumor cells chemokine receptors ccr4 melanoma cells depends cell priming represents european economic area key downstream mechanisms rowland-jones sl persistent virus infections antimelanoma activity conejo-garcia jr predicts reduced survival marincola fm nih r01 ca90575 melanoma article 04 melanoma tumor microenvironment conditions privacy policy cell receptor

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Tumor progression despite massive influx of activated CD8+ T cells in a patient with malignant melanoma ascites
         description:Although melanoma tumors usually express antigens that can be recognized by T cells, immune-mediated tumor rejection is rare. In many cases this is despite the presence of high frequencies of circulating tumor antigen-specific T cells, suggesting that tumor resistance downstream from T cell priming represents a critical barrier. Analyzing T cells directly from the melanoma tumor microenvironment, as well as the nature of the microenvironment itself, is central for understanding the key downstream mechanisms of tumor escape. In the current report we have studied tumor-associated lymphocytes from a patient with metastatic melanoma and large volume malignant ascites. The ascites fluid showed abundant tumor cells that expressed common melanoma antigens and retained expression of class I MHC and antigen processing machinery. The ascites fluid contained the chemokines CCL10, CCL15, and CCL18 which was associated with a large influx of activated T cells, including CD8+ T cells recognizing HLA-A2 tetramer complexes with peptides from Melan-A and NA17-A. However, several functional defects of these tumor antigen-specific T cells were seen, including poor production of IFN-γ in response to peptide-pulsed APC or autologous tumor cells, and lack of expression of perforin. Although these defects were T cell intrinsic, we also observed abundant CD4+CD25+FoxP3+ T cells, as well as transcripts for FoxP3, IL-10, PD-L1/B7-H1, and indoleamine-2,3-dioxygenase (IDO). Our observations suggest that, despite recruitment of large numbers of activated CD8+ T cells into the tumor microenvironment, T cell hyporesponsiveness and additional negative regulatory mechanisms can limit the effector phase of the anti-tumor immune response.
         datePublished:2006-02-09T00:00:00Z
         dateModified:2006-02-09T00:00:00Z
         pageStart:1185
         pageEnd:1197
         sameAs:https://doi.org/10.1007/s00262-005-0118-2
         keywords:
            Cytotoxic T cells
            Tumor immunity
            Tolerance
            Cell differentiation
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-005-0118-2/MediaObjects/262_2005_118_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-005-0118-2/MediaObjects/262_2005_118_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-005-0118-2/MediaObjects/262_2005_118_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-005-0118-2/MediaObjects/262_2005_118_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-005-0118-2/MediaObjects/262_2005_118_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-005-0118-2/MediaObjects/262_2005_118_Fig6_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-005-0118-2/MediaObjects/262_2005_118_Fig7_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-005-0118-2/MediaObjects/262_2005_118_Fig8_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-005-0118-2/MediaObjects/262_2005_118_Fig9_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-005-0118-2/MediaObjects/262_2005_118_Fig10_HTML.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:55
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Helena Harlin
               affiliation:
                     name:University of Chicago
                     address:
                        name:Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Todd V. Kuna
               affiliation:
                     name:University of Chicago
                     address:
                        name:Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Amy C. Peterson
               affiliation:
                     name:University of Chicago
                     address:
                        name:Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yuru Meng
               affiliation:
                     name:University of Chicago
                     address:
                        name:Department of Pathology, University of Chicago, Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Thomas F. Gajewski
               affiliation:
                     name:University of Chicago
                     address:
                        name:Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA
                        type:PostalAddress
                     type:Organization
                     name:University of Chicago
                     address:
                        name:Department of Pathology, University of Chicago, Chicago, USA
                        type:PostalAddress
                     type:Organization
                     name:University of Chicago
                     address:
                        name:Committees on Immunology and Cancer Biology, University of Chicago, Chicago, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Tumor progression despite massive influx of activated CD8+ T cells in a patient with malignant melanoma ascites
      description:Although melanoma tumors usually express antigens that can be recognized by T cells, immune-mediated tumor rejection is rare. In many cases this is despite the presence of high frequencies of circulating tumor antigen-specific T cells, suggesting that tumor resistance downstream from T cell priming represents a critical barrier. Analyzing T cells directly from the melanoma tumor microenvironment, as well as the nature of the microenvironment itself, is central for understanding the key downstream mechanisms of tumor escape. In the current report we have studied tumor-associated lymphocytes from a patient with metastatic melanoma and large volume malignant ascites. The ascites fluid showed abundant tumor cells that expressed common melanoma antigens and retained expression of class I MHC and antigen processing machinery. The ascites fluid contained the chemokines CCL10, CCL15, and CCL18 which was associated with a large influx of activated T cells, including CD8+ T cells recognizing HLA-A2 tetramer complexes with peptides from Melan-A and NA17-A. However, several functional defects of these tumor antigen-specific T cells were seen, including poor production of IFN-γ in response to peptide-pulsed APC or autologous tumor cells, and lack of expression of perforin. Although these defects were T cell intrinsic, we also observed abundant CD4+CD25+FoxP3+ T cells, as well as transcripts for FoxP3, IL-10, PD-L1/B7-H1, and indoleamine-2,3-dioxygenase (IDO). Our observations suggest that, despite recruitment of large numbers of activated CD8+ T cells into the tumor microenvironment, T cell hyporesponsiveness and additional negative regulatory mechanisms can limit the effector phase of the anti-tumor immune response.
      datePublished:2006-02-09T00:00:00Z
      dateModified:2006-02-09T00:00:00Z
      pageStart:1185
      pageEnd:1197
      sameAs:https://doi.org/10.1007/s00262-005-0118-2
      keywords:
         Cytotoxic T cells
         Tumor immunity
         Tolerance
         Cell differentiation
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-005-0118-2/MediaObjects/262_2005_118_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-005-0118-2/MediaObjects/262_2005_118_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-005-0118-2/MediaObjects/262_2005_118_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-005-0118-2/MediaObjects/262_2005_118_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-005-0118-2/MediaObjects/262_2005_118_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-005-0118-2/MediaObjects/262_2005_118_Fig6_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-005-0118-2/MediaObjects/262_2005_118_Fig7_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-005-0118-2/MediaObjects/262_2005_118_Fig8_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-005-0118-2/MediaObjects/262_2005_118_Fig9_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-005-0118-2/MediaObjects/262_2005_118_Fig10_HTML.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:55
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Helena Harlin
            affiliation:
                  name:University of Chicago
                  address:
                     name:Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Todd V. Kuna
            affiliation:
                  name:University of Chicago
                  address:
                     name:Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Amy C. Peterson
            affiliation:
                  name:University of Chicago
                  address:
                     name:Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yuru Meng
            affiliation:
                  name:University of Chicago
                  address:
                     name:Department of Pathology, University of Chicago, Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Thomas F. Gajewski
            affiliation:
                  name:University of Chicago
                  address:
                     name:Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA
                     type:PostalAddress
                  type:Organization
                  name:University of Chicago
                  address:
                     name:Department of Pathology, University of Chicago, Chicago, USA
                     type:PostalAddress
                  type:Organization
                  name:University of Chicago
                  address:
                     name:Committees on Immunology and Cancer Biology, University of Chicago, Chicago, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:55
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Chicago
      address:
         name:Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA
         type:PostalAddress
      name:University of Chicago
      address:
         name:Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA
         type:PostalAddress
      name:University of Chicago
      address:
         name:Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA
         type:PostalAddress
      name:University of Chicago
      address:
         name:Department of Pathology, University of Chicago, Chicago, USA
         type:PostalAddress
      name:University of Chicago
      address:
         name:Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA
         type:PostalAddress
      name:University of Chicago
      address:
         name:Department of Pathology, University of Chicago, Chicago, USA
         type:PostalAddress
      name:University of Chicago
      address:
         name:Committees on Immunology and Cancer Biology, University of Chicago, Chicago, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Helena Harlin
      affiliation:
            name:University of Chicago
            address:
               name:Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA
               type:PostalAddress
            type:Organization
      name:Todd V. Kuna
      affiliation:
            name:University of Chicago
            address:
               name:Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA
               type:PostalAddress
            type:Organization
      name:Amy C. Peterson
      affiliation:
            name:University of Chicago
            address:
               name:Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA
               type:PostalAddress
            type:Organization
      name:Yuru Meng
      affiliation:
            name:University of Chicago
            address:
               name:Department of Pathology, University of Chicago, Chicago, USA
               type:PostalAddress
            type:Organization
      name:Thomas F. Gajewski
      affiliation:
            name:University of Chicago
            address:
               name:Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA
               type:PostalAddress
            type:Organization
            name:University of Chicago
            address:
               name:Department of Pathology, University of Chicago, Chicago, USA
               type:PostalAddress
            type:Organization
            name:University of Chicago
            address:
               name:Committees on Immunology and Cancer Biology, University of Chicago, Chicago, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA
      name:Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA
      name:Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA
      name:Department of Pathology, University of Chicago, Chicago, USA
      name:Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA
      name:Department of Pathology, University of Chicago, Chicago, USA
      name:Committees on Immunology and Cancer Biology, University of Chicago, Chicago, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(111)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.29s.

LINK . SPRINGER . COM {}